Tyler is responsible for advancing translatable indications as a part of the Preclinical Development team at Life Edit, leveraging over eight years of experience in the gene therapy and gene editing fields using a variety of preclinical models.

Before joining Life Edit, Tyler worked as a post-doctoral fellow at Duke University investigating the consequences of immunological responses against in vivo gene editing in order to advance therapeutic strategies for Duchenne’s Muscular Dystrophy.

Previously, Tyler received his Master of Health Science at Johns Hopkins School of Public Health and went on to work with the FDA for a short time before completing his PhD in Genetics from his undergraduate alma mater, the University of Florida (Go Gators!). During his graduate studies there, he helped develop a CRISPR-based strategy to treat congenital blindness.